Ponatinib Hydrochloride Patent Expiration
Ponatinib Hydrochloride is used for treating various types of leukemia, including acute lymphoblastic leukemia, chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia. It was first introduced by Takeda Pharmaceuticals Usa Inc
Ponatinib Hydrochloride Patents
Given below is the list of patents protecting Ponatinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Iclusig | US11192895 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | Dec 12, 2033 | Takeda Pharms Usa |
| Iclusig | US11192897 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | Dec 12, 2033 | Takeda Pharms Usa |
| Iclusig | US11384086 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | Dec 12, 2033 | Takeda Pharms Usa |
| Iclusig | US9493470 | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | Dec 12, 2033 | Takeda Pharms Usa |
| Iclusig | US8114874 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | Jan 24, 2027 | Takeda Pharms Usa |
| Iclusig | US9029533 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | Dec 22, 2026 | Takeda Pharms Usa |
Ponatinib Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Ponatinib Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Ponatinib Hydrochloride.
Given below is the list of companies who have filed for Ponatinib Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Ponatinib Hydrochloride. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 15MG BASE | tablet | Discontinued | ORAL | N/A | Jul 14, 2023 |
| EQ 45MG BASE | tablet | Discontinued | ORAL | N/A | Jul 14, 2023 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||